Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42 nd Annual Go...
Despite a ~7.5% gain yesterday, Prelude Therapeutics ([[PRLD]] -2.1%) has resumed its recent losing streak today.Earlier this week, it was reported that its largest institutional investor Orbimed Advisors has cut its ownership stake at the company to ~21.6% with the sale of 5.5...
Prelude Therapeutics (PRLD): Q1 GAAP EPS of -$0.47 misses by $0.05.Cash and cash equivalents of $362.99M.Press Release For further details see: Prelude Therapeutics EPS misses by $0.05
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing...
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Off...
The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ra...
Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...
The following slide deck was published by Prelude Therapeutics Incorporated in conjunction with this event. For further details see: Prelude Therapeutics (PRLD) Investor Presentation - Slideshow
Prelude Therapeutics (PRLD): Q4 GAAP EPS of -$0.45 beats by $0.13.Cash and cash equivalents of $218.3M as of December 31, 2020Press Release For further details see: Prelude Therapeutics EPS beats by $0.13
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Prelude Therapeutics Incorporated Website:
2024-07-27 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 07:00:07 ET Peter Lawson from Barclays issued a price target of $3.00 for PRLD on 2024-06-20 05:33:00. The adjusted price target was set to $3.00. At the time of the announcement, PRLD was trading at $3.87. The overall price target consensus is at $10.67 with ...
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2...